These findings support the association between sKIT reduction and improved clinical outcome reported by Zhu et al. in a phase II study of sunitinib in HCC [13], and suggest that inhibition of KIT signaling may contribute to sunitinib antitumor activity. This evidence concerns the gene KIT and hepatocellular carcinoma.